Jameie, M., Azizmohammad Looha, M., Ebadi, Z., Amanollahi, M., Amani, K., Nobahari, F., . . . Harirchian, M. H. (2024). Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies. BMC Neurology, 24(1), . https://doi.org/10.1186/s12883-024-03793-y
Chicago-referens (17:e uppl.)Jameie, Melika, et al. "Immunogenicity, Clinical Efficacy, and Safety of the Sinopharm (BBIBP-CorV) SARS-CoV-2 Vaccine Among People with Multiple Sclerosis Receiving Disease-modifying Therapies." BMC Neurology 24, no. 1 (2024). https://doi.org/10.1186/s12883-024-03793-y.
MLA-referens (9:e uppl.)Jameie, Melika, et al. "Immunogenicity, Clinical Efficacy, and Safety of the Sinopharm (BBIBP-CorV) SARS-CoV-2 Vaccine Among People with Multiple Sclerosis Receiving Disease-modifying Therapies." BMC Neurology, vol. 24, no. 1, 2024, https://doi.org/10.1186/s12883-024-03793-y.
